Zenosense, Inc. (OTC Pink: ZENO) is engaged as a healthcare technology company, which develops the MIDS Cardiac handheld device. Shares of the medical device manufacturer are gaining 7.13%, through afternoon trading on Thursday, June 15, 2017. Over the past month, Zenosense, Inc. has seen average daily volume of 127,513 shares. However, volume of 189,773 shares or dollar volume of $89,193, has already exchanged hands on Thursday.
Shares of Zenosense, Inc. are rallying today, after the company announced that it has been issued a U.S. patent for its MIDS technology. The company has already obtained a patent for the same technology in China. Here is the full press release detailing of the U.S. patent award:
Zenosense, Inc. Press Release:
VALENCIA, SPAIN–(Marketwired – Jun 15, 2017) – Zenosense, Inc. (OTC PINK: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection of certain cardiac event biomarkers to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected acute myocardial infarction (heart attack), is pleased to announce that its MIDS Medical Limited joint venture (“MML”) based at Sci-Tech, Daresbury (UK), has received notice of a patent issuance in the U.S.
Our joint venture partner in MML has received a United States Patent and Trademark Office grant for the issuance of the central MIDS patent under number 9,678,064 in the U.S., namely: “Immunoassay Apparatus Incorporating Microfluidic Channel”.
This is as a result of a patent application originally filed in 2011 by our MML joint venture partner. It is one of a number of applications made in commercially crucial regions for patent protection of the central MIDS detection technology.
The same MIDS patent has already been granted in China. Other applications have also successfully progressed into the national phase in the EU and India. This issuance in the U.S. indicates that these latter territories are also likely to progress to grant and, if so, will establish intellectual property protection in these key commercial regions. The MIDS patents are under license for the exclusive use by MML and will be transferred directly to MML in the event of the conclusion of a relevant commercial deal with a third party.
Carlos Gil, CEO of Zenosense Inc., commented: “This latest grant of the MIDS patent in the U.S. further validates our confidence in the ability of the MML team to deliver this exciting technology. I also expect to be able to provide a further update on development activities in the coming weeks.”
About Zenosense, Inc.
Zenosense Inc.’s primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac™, and is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients.
To find out more about Zenosense (OTC PINK: ZENO), visit our website at www.zenosense.com.
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 filed on filed on April 17, 2017, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.